Matthew Kulke, MD
Several emerging agents are rapidly advancing the treatment paradigm for patients with neuroendocrine tumors (NETs).
, Matthew Kulke, MD, a medical oncologist at Dana-Farber Cancer Institute, discussed the evolving treatment paradigm for patients with NETs.
OncLive: What exciting advancements have occurred in the treatment of patients with NETs?
: There are several new treatments that are focused on tumor control for patients with NETs. For example, there is a phase II study of cabozantinib, a tyrosine kinase inhibitor that targets VEGF and c-MET. The study showed encouraging results, leading us to believe that cabozantinib will be taken forward into a large randomized trial that is designed as a registration study. Hopefully, we will get another new treatment for patients with NETs.
... to read the full story